Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations

Authors

  • L. A. O'BRIEN,

    1. Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, K7L 3 N6, Canada; *Department of Chemistry, Queen's University, Kingston, Ontario, K7L 3 N6, Canada; and †Departments of Medicine and Chemistry, and School of Biomedical Engineering, Dalhousie University, Halifax, Nova Scotia, B3H 4J3, Canada
    Search for more papers by this author
  • J. J. SUTHERLAND,

    1. Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, K7L 3 N6, Canada; *Department of Chemistry, Queen's University, Kingston, Ontario, K7L 3 N6, Canada; and †Departments of Medicine and Chemistry, and School of Biomedical Engineering, Dalhousie University, Halifax, Nova Scotia, B3H 4J3, Canada
    Search for more papers by this author
  • D. F. WEAVER,

    1. Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, K7L 3 N6, Canada; *Department of Chemistry, Queen's University, Kingston, Ontario, K7L 3 N6, Canada; and †Departments of Medicine and Chemistry, and School of Biomedical Engineering, Dalhousie University, Halifax, Nova Scotia, B3H 4J3, Canada
    Search for more papers by this author
  • D. LILLICRAP

    1. Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, K7L 3 N6, Canada; *Department of Chemistry, Queen's University, Kingston, Ontario, K7L 3 N6, Canada; and †Departments of Medicine and Chemistry, and School of Biomedical Engineering, Dalhousie University, Halifax, Nova Scotia, B3H 4J3, Canada
    Search for more papers by this author

Dr David Lillicrap, Department of Pathology and Molecular Medicine, Richardson Laboratory, Queens University, Kingston, Canada, K7L 3N6.
Tel.: 613-548-1304; fax: 613-548-1356; email: lillicrap@cliff.path.queensu.ca

No abstract is available for this article.

Ancillary